Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 10, 2012 - Issue 11
Submit an article Journal homepage
257
Views
10
CrossRef citations to date
0
Altmetric
Clinical Trial Report

The MOTIVATE trials: maraviroc therapy in antiretroviral treatment-experienced HIV-1-infected patients

Steven FL van Lelyveld Department of Internal Medicine and Infectious Diseases, University Medical Center Utrecht, Huispostnummer F.02.126, Postbus 85500, 3508 GA Utrecht, The Netherlands; Department of Internal Medicine and Infectious Diseases, University Medical Center Utrecht, Huispostnummer F.02.126, Postbus 85500, 3508 GA Utrecht, The Netherlands. [email protected]
,
Annemarie MJ Wensing Department of Virology, Medical Microbiology, University Medical Center Utrecht, Huispostnummer F.02.126, Postbus 85500, 3508 GA Utrecht, The Netherlands; Department of Virology, Medical Microbiology, University Medical Center Utrecht, Huispostnummer F.02.126, Postbus 85500, 3508 GA Utrecht, The Netherlands
&
Andy IM Hoepelman Department of Internal Medicine and Infectious Diseases, University Medical Center Utrecht, Huispostnummer F.02.126, Postbus 85500, 3508 GA Utrecht, The Netherlands; Department of Internal Medicine and Infectious Diseases, University Medical Center Utrecht, Huispostnummer F.02.126, Postbus 85500, 3508 GA Utrecht, The Netherlands
Pages 1241-1247 | Published online: 10 Jan 2014

References

  • Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338(13), 853–860 (1998).
  • Jensen-Fangel S, Pedersen L, Pedersen C et al. Low mortality in HIV-infected patients starting highly active antiretroviral therapy: a comparison with the general population. AIDS 18(1), 89–97 (2004).
  • Lewden C, Chene G, Morlat P et al.; Agence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS) CO8 APROCO-COPILOTE Study Group; Agence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS) CO3 AQUITAINE Study Group. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J. Acquir. Immune Defic. Syndr. 46(1), 72–77 (2007).
  • van Sighem AI, Gras LA, Reiss P, Brinkman K, de Wolf F; ATHENA National Observational Cohort Study. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS 24(10), 1527–1535 (2010).
  • Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu. Rev. Med. 62, 141–155 (2011).
  • Johnson M, Sabin C, Girardi E. Definition and epidemiology of late presentation in Europe. Antivir. Ther. (London) 15(Suppl. 1), 3–8 (2010).
  • Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 372, 293–299 (2008).
  • Sabin CA, Worm SW, Weber R et al.; D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 371(9622), 1417–1426 (2008).
  • Worm SW, Sabin C, Weber R et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J. Infect. Dis. 201(3), 318–330 (2010).
  • Vercauteren J, Wensing AM, van de Vijver DA et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J. Infect. Dis. 200(10), 1503–1508 (2009).
  • Bannister WP, Cozzi-Lepri A, Kjær J et al.; EuroSIDA group. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy. J. Antimicrob. Chemother. 66(4), 901–911 (2011).
  • Gulick RM, Lalezari J, Goodrich J et al.; MOTIVATE Study Teams. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 359(14), 1429–1441 (2008).
  • Fätkenheuer G, Nelson M, Lazzarin A et al.; MOTIVATE 1 and MOTIVATE 2 Study Teams. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N. Engl. J. Med. 359(14), 1442–1455 (2008).
  • Corbeau P, Reynes J. CCR5 antagonism in HIV infection: ways, effects, and side effects. AIDS 23(15), 1931–1943 (2009).
  • Berson JF, Long D, Doranz BJ, Rucker J, Jirik FR, Doms RW. A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. J. Virol. 70(9), 6288–6295 (1996).
  • Deng H, Liu R, Ellmeier W et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381(6584), 661–666 (1996).
  • Esté JA, Telenti A. HIV entry inhibitors. Lancet 370(9581), 81–88 (2007).
  • Vandekerckhove LP, Wensing AM, Kaiser R et al.; European Consensus Group on Clinical Management of Tropism Testing. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect. Dis. 11(5), 394–407 (2011).
  • Liu R, Paxton WA, Choe S et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86(3), 367–377 (1996).
  • Nguyêñ GT, Carrington M, Beeler JA et al. Phenotypic expressions of CCR5-delta32/delta32 homozygosity. J. Acquir. Immune Defic. Syndr. 22(1), 75–82 (1999).
  • Lim JK, Louie CY, Glaser C et al. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J. Infect. Dis. 197(2), 262–265 (2008).
  • Fätkenheuer G, Pozniak AL, Johnson MA et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med. 11(11), 1170–1172 (2005).
  • Nichols WG, Steel HM, Bonny T et al. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob. Agents Chemother. 52(3), 858–865 (2008).
  • Koot M, Keet IP, Vos AH et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann. Intern. Med. 118(9), 681–688 (1993).
  • Saag M, Goodrich J, Fätkenheuer G et al.; A4001029 Study Group. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J. Infect. Dis. 199(11), 1638–1647 (2009).
  • Swenson LC, Mo T, Dong WW et al. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J. Infect. Dis. 203(2), 237–245 (2011).
  • Hardy WD, Gulick RM, Mayer H et al. Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. J. Acquir. Immune Defic. Syndr. 55(5), 558–564 (2010).
  • Reuter S, Braken P, Jensen B et al. Maraviroc in treatment-experienced patients with HIV-1 infection – experience from routine clinical practice. Eur. J. Med. Res. 15(6), 231–237 (2010).
  • Genebat M, Ruiz-Mateos E, Pulido I et al. Long-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practice. Curr. HIV Res. 8(6), 482–486 (2010).
  • Nozza S, Galli L, Visco F et al. Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience. AIDS 24(6), 924–928 (2010).
  • Whitcomb JM, Huang W, Fransen S et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob. Agents Chemother. 51(2), 566–575 (2007).
  • Su Z, Gulick RM, Krambrink A et al.; AIDS Clinical Trials Group A5211 Team. Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. J. Infect. Dis. 200(11), 1724–1728 (2009).
  • Raymond S, Delobel P, Mavigner M et al. Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage. J. Clin. Virol. 47(2), 126–130 (2010).
  • Kootstra NA, Schuitemaker H. Determination of cell tropism of HIV-1. Methods Mol. Biol. 304, 317–325 (2005).
  • Hamy F, Garcia O, Klimkait T. Coreceptor tropism of HIV in clinical samples dissected by rPhenotyping. Presented at: The 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia, 22–25 July 2007.
  • McGovern RA, Thielen A, Mo T et al. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS 24(16), 2517–2525 (2010).
  • Recordon-Pinson P, Soulié C, Flandre P et al.; ANRS AC11 Resistance Study Group. Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study. Antimicrob. Agents Chemother. 54(8), 3335–3340 (2010).
  • Waters LJ, Scourfield AT, Marcano M et al. The evolution of coreceptor tropism in HIV-infected patients interrupting suppressive antiretroviral therapy. Clin. Infect. Dis. 52(5), 671–673 (2011).
  • Symons J, van Lelyveld SF, Hoepelman AI et al. Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient. J. Antimicrob. Chemother. 66(4), 890–895 (2011).
  • Svicher V, Balestra E, Cento V et al. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro. Antiviral Res. 90(1), 42–53 (2011).
  • Seclen E, Gonzalez Mdel M, Lapaz M et al. Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients. J. Antimicrob. Chemother. 65, 2502–2504 (2010).
  • Dorr P, Westby M, Dobbs S et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49(11), 4721–4732 (2005).
  • Perry CM. Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection. Drugs 70(9), 1189–1213 (2010).
  • Portsmouth S, Craig C, Mills A et al. 48-week results of a dual-therapy regimen of once-daily maraviroc (MVC) 150 mg in combination with ritonavir-boosted atazanavir (ATV/r) compared to emtricitabine/tenofovir (FTC/TDF) + ATV/r in treatment-naive (TN) patients infected with CCR5-tropic HIV-1. Presented at: The 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy, 17–20 July 2011.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.